NCT02875132View on ClinicalTrials.gov

Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 15, 2017

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Acral Lentiginous Melanoma
Interventions
DRUG

pembrolizumab

pembrolizumab at 200mg IV infusion every 3 weeks

Trial Locations (1)

Unknown

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER

NCT02875132 - Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma | Biotech Hunter | Biotech Hunter